ArticleGland surgery2026
Omission of intraoperative frozen section in sentinel lymph node biopsy for early breast cancer: impact on survival outcomes.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The implementation of sentinel lymph node biopsy (SLNB) with permanent section (PS) analysis alone in patients who satisfied the ACOSOG Z0011 criteria did not alter the standard of care offered by the additional frozen section (FS) analysis. This study reports the patient survival outcomes of early-stage breast cancer based on SLNB techniques. Methods: Our previous investigation examined 453 SLNB cases at King Chulalongkorn Memorial Hospital, with follow-up concluding on April 15, 2025. The retrospective cohort study included patients diagnosed with clinically node-negative primary invasive breast cancer, who underwent breast-conserving surgery. The primary endpoint was 5-year disease-free survival (DFS), while secondary outcomes encompassed the overall cumulative incidence of local, distant, and axillary recurrence, as well as overall survival (OS). Results: Of the 453 patients undergoing SLNB, 239 underwent SLNB with PS alone, while 214 received additional FS. Kaplan-Meier analysis demonstrated a statistically significant difference in DFS between groups (log-rank P=0.008). In multivariable Cox regression analysis, with the FS group as the reference, the PS group showed a lower estimated risk of recurrence [hazard ratio (HR): 0.34; 95% confidence interval (CI): 0.15-0.79]. The 5-year DFS rates were 95.8% in the PS group and 93.5% in the FS group; however, this difference was not statistically significant when compared using crude event rates (P=0.26). OS was similar between groups (P=0.60). In the PS group, local and distant recurrence rates were 1.3% and 2.5%, respectively, with no regional recurrences observed. Conclusions: Based on the DFS and OS outcomes from our 5-year follow-up data, SLNB with PS analysis alone in patients meeting the ACOSOG Z0011 criteria was found to be comparable to SLNB with FS analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.